Silence Therapeutics plc
SLNCF
$0.95
$0.451490.53%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 43.52M | 19.97M | 22.02M | 32.66M | 30.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.52M | 19.97M | 22.02M | 32.66M | 30.74M |
| Cost of Revenue | 12.01M | 11.18M | 9.61M | 9.82M | 12.52M |
| Gross Profit | 31.51M | 8.78M | 12.42M | 22.84M | 18.22M |
| SG&A Expenses | 27.29M | 25.69M | 24.68M | 24.41M | 25.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.46M | 83.87M | 72.68M | 74.54M | 82.11M |
| Operating Income | -50.94M | -63.90M | -50.65M | -41.88M | -51.36M |
| Income Before Tax | -46.17M | -73.77M | -48.02M | -41.05M | -52.17M |
| Income Tax Expenses | 647.60K | 869.00K | 1.91M | 2.27M | 1.16M |
| Earnings from Continuing Operations | -46.82 | -74.64 | -49.93 | -43.32 | -53.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.82M | -74.64M | -49.93M | -43.32M | -53.33M |
| EBIT | -50.94M | -63.90M | -50.65M | -41.88M | -51.36M |
| EBITDA | -50.34M | -63.31M | -50.05M | -41.28M | -50.75M |
| EPS Basic | -3.01 | -5.01 | -3.61 | -3.43 | -4.30 |
| Normalized Basic EPS | -0.62 | -1.01 | -0.71 | -0.68 | -0.89 |
| EPS Diluted | -3.01 | -5.01 | -3.61 | -3.43 | -4.30 |
| Normalized Diluted EPS | -0.62 | -1.01 | -0.71 | -0.68 | -0.89 |
| Average Basic Shares Outstanding | 184.99M | 176.68M | 166.92M | 156.35M | 148.37M |
| Average Diluted Shares Outstanding | 61.66M | 58.89M | 55.64M | 52.12M | 49.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |